Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. MicroPort Scientific Corporation
  6. News
  7. Summary
    853   KYG608371046

MICROPORT SCIENTIFIC CORPORATION

(853)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

MicroPort Scientific : « EP Represented in the 19th International Forum on Atrial Fibrillation

07/20/2021 | 09:59pm EDT

Dalian, China, 21 July 2021 - Shanghai MicroPort EP MedTech Co., Ltd. (MicroPort® EP) was recently represented at the 19th International Forum on Atrial Fibrillation (CAFS 2021). The forum, themed, 'New Concept, New Approach, New Future', looked at key milestones in the field of treatments for atrial fibrillation over the past 20 years, whilst also looking towards future development in the field. During the Forum, MicroPort® EP attracted wide attention from practitioners through presentations and demonstrations of its Columbus®️ 3D EP Navigation System V3, which features electromagnetic positioning.

MicroPort® EP also held a satellite session entitled, 'Strengthening Chinese brands: AF diagnosis and treatment supported by MicroPort® EP'. This session involved an exchange of case studies, experience in the use of consumables, procedures, and the application of electrophysiological devices in the context of China's medical insurance system. The efforts of MicroPort® EP were recognized by experts in attendance, including Professor Fengmin Lu from the Tianjin Chest Hospital who noted that he was 'pleased to see the advances and innovation of Chinese medical devices.'

Professor Shaolong Li from the Yan'an Hospital affiliated to Kunming Medical University, gave a detailed introduction to the relationship between the aortic sinus and the left and right atria through a case study of ablation of focal atrial tachycardia from the non-coronary aortic sinus, which was guided by the Columbus®️ 3D EP Navigation System. Using the Columbus® system to map the internal structures, he completed the ablation in less than 40 minutes.

Similarly, other experienced physicians made presentations on their experiences with MicroPort® EP's products, including Professor Guojian Sun from the Zhejiang Greentown International Cardiovascular Hospital, who presented his experience with the use of MicroPort® EP's Steerable Introducer in atrial fibrillation cases. Professor Guojian Sun stated his belief that 'the clinical experience of MicroPort® EP's Steerable Introducer is comparable to that of imported devices both in vitro and in vivo'.

As the leading electrophysiological medical device company in China, MicroPort® EP is committed to providing quality and affordable products and services. In the future, MicroPort® EP will continue to devote itself to the field of cardiac arrhythmias, provide more electrophysiologists around the world with easy and safe diagnostic devices, and enable more patients with cardiac arrhythmias to receive more effective treatment and enjoy a healthier life.

About MicroPort® EP

Shanghai MicroPort EP MedTech Co., Ltd, a subsidiary of MicroPort Scientific Corporation (MicroPort®, stock code: 00853.HK), was established in the Shanghai International Medical Zone on August 31, 2010. Its concentration is on the development, manufacture, and marketing of minimally invasive medical devices for the treatment of electrophysiological diseases, including cardiac ablation catheters, diagnostic catheters, 3D navigation systems, amongst others.

Disclaimer

MicroPort Scientific Corporation published this content on 21 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 July 2021 01:58:04 UTC.


ę Publicnow 2021
All news about MICROPORT SCIENTIFIC CORPORATION
09/13MICROPORT SCIENTIFIC : Acquiring 45% Stake in Immunosuppressants Maker for $17 Million
MT
09/12MICROPORT SCIENTIFIC : « Announces Strategic Investment with Kerui Pharma
PU
09/10MICROPORT SCIENTIFIC : « NeuroTech NUMEN Coil Embolization System Approved for Market in K..
PU
09/08MICROPORT SCIENTIFIC : Products Complete First Implantations in the UK Following Endovaste..
PU
09/07MICROPORT SCIENTIFIC : « Toumai« Laparoscopic Surgery Robot Becomes First in China to Comp..
PU
09/01MICROPORT SCIENTIFIC : First Motorized Retrievable Transcatheter Aortic Valve (TAVI) Syste..
PU
08/31MICROPORT SCIENTIFIC : Loss Rises on Higher R&D Spending, Price Reduction
MT
08/29MICROPORT SCIENTIFIC : « EP OptimAblate™ Tubing Set Receives NMPA Marketing Approval
PU
08/24MICROPORT SCIENTIFIC : MSC Completes First Patient Enrollment for Multicenter Post-Marketi..
PU
08/12MICROPORT SCIENTIFIC : CardioFlow Medtech's Next-generation Alwide« Plus Balloon Catheter ..
PU
More news
Financials (USD)
Sales 2021 783 M - -
Net income 2021 -167 M - -
Net cash 2021 980 M - -
P/E ratio 2021 -538x
Yield 2021 0,01%
Capitalization 88 332 M 11 346 M -
EV / Sales 2021 112x
EV / Sales 2022 89,5x
Nbr of Employees 8 303
Free-Float 45,2%
Chart MICROPORT SCIENTIFIC CORPORATION
Duration : Period :
MicroPort Scientific Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MICROPORT SCIENTIFIC CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 49,25 $
Average target price 7,43 $
Spread / Average Target -84,9%
EPS Revisions
Managers and Directors
Zhao Hua Chang Chairman & Chief Executive Officer
Hong Bin Sun Chief Financial Officer
Qi Yi Luo Chief Technology Officer
Glendy Wang Chief Operating Officer
Jonathan H. Chou Independent Non-Executive Director
Sector and Competitors